Skip to content
2000
image of Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility
file format pdf download PDF

Abstract

Despite the global prevalence of herbal medicine use and the common perception of their safety, substantial evidence indicates a significant potential for clinically relevant herb-drug interactions that may affect the pharmacokinetics and pharmacodynamics of co-administered pharmaceuticals. This critical issue poses a considerable threat to patient safety and the effectiveness of conventional treatments, primarily through modulation of the cytochrome P450 (CYP450) enzyme system, a key metabolic pathway for many drugs. This research aims to elucidate how herbal remedies affect CYP450 enzyme activity, thereby influencing drug pharmacokinetics. Our methodology involves a comprehensive critical evaluation of existing scientific data from , , and studies, clinical trials, and meta-analyses to identify specific herbal medicines with significant effects on CYP450. The investigation outlines their mechanisms of action, distinguishing between enzyme induction, which can diminish drug efficacy, and inhibition, which may lead to increased drug concentrations and toxicity. It was highlighted that certain medicinal plants and their bioactive compounds may act as inducers or inhibitors across major isoforms, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. Comprehensive data were compiled for ten plant species with the most extensive scientific information regarding their effects on CYP450, namely St John’s wort ( L.), Echinacea ( (L.) Moench), Ginkgo ( L.), Danshen ( Bunge), Garlic ( L.), Ginger ( Roscoe), Milk thistle ( L. Gaertn.), Black cohosh ( L.), Ginseng ( C.A. Mey), and Liquorice ( L.). Ultimately, this study underscores the vital role of the CYP450 system in mediating these interactions and advocates for increased awareness among healthcare professionals and patients. Looking ahead, conducting robust, standardised clinical trials, developing predictive interaction models, and performing comprehensive analyses of herbal constituents are crucial to ensuring safe and effective pharmacotherapy involving herbal medicines.

© 2026 The Author(s). Published by Bentham Science Publisher.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673428595251209114801
2026-02-26
2026-03-08

  • From This Site

    /content/journals/cmc/10.2174/0109298673428595251209114801
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmc/10.2174/0109298673428595251209114801/BMS-CMC-2025-577.html?itemId=/content/journals/cmc/10.2174/0109298673428595251209114801&mimeType=html&fmt=ahah

References

  1. Brantley S.J. Argikar A.A. Lin Y.S. Nagar S. Paine M.F. Herb-drug interactions: Challenges and opportunities for improved predictions. Drug Metab. Dispos. 2014 42 3 301 317 10.1124/dmd.113.055236 24335390
    [Google Scholar]
  2. Spanakis M. Tzamali E. Tzedakis G. Koumpouzi C. Pediaditis M. Tsatsakis A. Sakkalis V. Artificial intelligence models and tools for the assessment of drug–herb interactions. Pharmaceuticals 2025 18 3 282 10.3390/ph18030282 40143062
    [Google Scholar]
  3. Herbal medicine market size, share & industry analysis, by form (powder, liquid & gel, and tablets & capsules), by application (pharmaceutical & nutraceutical, food & beverages, and personal care & beauty products), and regional forecast. 2025 Available from: https://www.fortunebusinessinsights.com/herbal-medicine-market-106320
  4. Choudhury A. Singh P.A. Bajwa N. Dash S. Bisht P. Pharmacovigilance of herbal medicines: Concerns and future prospects. J. Ethnopharmacol. 2023 309 116383 10.1016/j.jep.2023.116383 36918049
    [Google Scholar]
  5. Mortada E.M. Evidence-based complementary and alternative medicine in current medical practice. Cureus 2024 16 1 52041 10.7759/cureus.52041 38344508
    [Google Scholar]
  6. Gasmi A. Kanwal S. Oliinyk P. Lysiuk R. Shanaida M. Gasmi Benahmed A. Dushmantha W.K.T. Arshad M. Kernychna I. Lenchyk L. Upyr T. Shanaida V. Bjørklund G. Ayurvedic and chinese herbs against coronaviruses. Curr. Pharm. Des. 2024 30 21 1681 1698 10.2174/0113816128269864231112094917 38685809
    [Google Scholar]
  7. Bukowska B. Grzegorowska A. Szczerkowska-Majchrzak E. Bukowski K. Kadac-Czapska K. Grembecka M. Hazardous interactions between food, herbs, and drugs in the first stage of biotransformation: Case reports of adverse drug interactions in humans. Int. J. Mol. Sci. 2025 26 11 5188 10.3390/ijms26115188
    [Google Scholar]
  8. Izzo A.A. Ernst E. Interactions between herbal medicines and prescribed drugs: An updated systematic review. Drugs 2009 69 13 1777 1798 10.2165/11317010‑000000000‑00000 19719333
    [Google Scholar]
  9. Zhao M. Ma J. Li M. Zhang Y. Jiang B. Zhao X. Huai C. Shen L. Zhang N. He L. Qin S. Cytochrome p450 enzymes and drug metabolism in humans. Int. J. Mol. Sci. 2021 22 23 12808 10.3390/ijms222312808 34884615
    [Google Scholar]
  10. Chen H. Zhang X. Feng Y. Rui W. Shi Z. Wu L. Bioactive components of Glycyrrhiza uralensis mediate drug functions and properties through regulation of CYP450 enzymes. Mol. Med. Rep. 2014 10 3 1355 1362 10.3892/mmr.2014.2331 24939038
    [Google Scholar]
  11. Wang S. Li W. Yang J. Yang Z. Yang C. Jin H. Research progress of herbal medicines on drug metabolizing enzymes: Consideration based on toxicology. Curr. Drug Metab. 2020 21 12 913 927 10.2174/1389200221999200819144204 32819254
    [Google Scholar]
  12. Nicolussi S. Drewe J. Butterweck V. Meyer zu Schwabedissen H.E. Clinical relevance of St. John’s wort drug interactions revisited. Br. J. Pharmacol. 2020 177 6 1212 1226 10.1111/bph.14936 31742659
    [Google Scholar]
  13. Manikandan P. Nagini S. Cytochrome P450 structure, function and clinical significance: A review. Curr. Drug Targets 2018 19 1 38 54 28124606
    [Google Scholar]
  14. Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients; NCT05081583. 2024 Available from: https://clinicaltrials.gov/study/NCT05081583
  15. Herb-Opioid Interactions; NCT00027014. 2007 Available from: https://clinicaltrials.gov/study/NCT00027014
  16. Effect of Moringa oleifera on metformin plasma level in type 2 diabetes mellitus patients; NCT03189407. 2017 Available from: https://clinicaltrials.gov/study/NCT03189407?cond=Herb-drug
  17. Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction; NCT01410058. 2019 Available from: https://clinicaltrials.gov/study/NCT01410058
  18. Drug interactions between Echinacea purpurea and etravirine; NCT01347658. 2019 Available from: https://clinicaltrials.gov/study/NCT01347658?term=Herb-drug
  19. Drug interactions between Echinacea purpurea and darunavir/ritonavir; NCT01046890. 2019 Available from: https://clinicaltrials.gov/study/NCT01046890?term=Herb-drug
  20. Resveratrol and midazolam metabolism; NCT01173640. 2017 Available from: https://clinicaltrials.gov/study/NCT01173640?term=Herb-drug
  21. The use of cannabidiol in cancer patients (CANPADIOL); NCT05407298. 2022 Available from: https://clinicaltrials.gov/study/NCT05407298?term=Herb-drug
  22. The interaction of herbs and statins; NCT05072405. 2021 Available from: https://clinicaltrials.gov/study/NCT05072405?cond=Herb-drug
  23. Screening Herbs for Drug Interactions. NCT00029263. 2006 Available from: https://clinicaltrials.gov/study/NCT00029263
  24. Anwar F. Latif S. Ashraf M. Gilani A. H. Moringa oleifera: A food plant with multiple medicinal uses. Phytother. Res. 2007 21 1 17 25 10.1002/ptr.2023 17089328
    [Google Scholar]
  25. Education intervention in encouraging health providers to talk with cancer patients about the use of complementary and alternative medicine. NCT00608933. 2020 Available from: https://clinicaltrials.gov/study/NCT00608933?term=Herb-drug
  26. Fantoukh O.I. Albadry M.A. Parveen A. Hawwal M.F. Majrashi T. Ali Z. Khan S.I. Chittiboyina A.G. Khan I.A. Isolation, synthesis, and drug interaction potential of secondary metabolites derived from the leaves of miracle tree (Moringa oleifera) against CYP3A4 and CYP2D6 isozymes. Phytomedicine 2019 60 153010 10.1016/j.phymed.2019.153010 31301970
    [Google Scholar]
  27. Almazroo O.A. Miah M.K. Venkataramanan R. Drug Metabolism in the Liver. Clin. Liver Dis. 2017 21 1 1 20 10.1016/j.cld.2016.08.001 27842765
    [Google Scholar]
  28. Eikelenboom-Schieveld S.J.M. Fogleman J.C. Psychoactive medication, violence, and variant alleles for cytochrome p450 genes. J. Pers. Med. 2021 11 5 426 10.3390/jpm11050426 34069803
    [Google Scholar]
  29. Eikelenboom-Schieveld S.J.M. Fogleman J.C. Cytochrome P450 genes: Their role in drug metabolism and violence. Handb anger. Aggress Violence. 2022 84 1 29
    [Google Scholar]
  30. Patel R. Barker J. ElShaer A. Pharmaceutical excipients and drug metabolism: A mini-review. Int. J. Mol. Sci. 2020 21 21 8224 10.3390/ijms21218224 33153099
    [Google Scholar]
  31. Xu L.H. Du Y.L. Rational and semi-rational engineering of cytochrome P450s for biotechnological applications. Synth. Syst. Biotechnol. 2018 3 4 283 290 10.1016/j.synbio.2018.10.001 30533540
    [Google Scholar]
  32. Li Z. Jiang Y. Guengerich F.P. Ma L. Li S. Zhang W. Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications. J. Biol. Chem. 2020 295 3 833 849 10.1016/S0021‑9258(17)49939‑X 31811088
    [Google Scholar]
  33. Nelson D.R. The cytochrome p450 homepage. Hum. Genomics 2009 4 1 59 65 10.1186/1479‑7364‑4‑1‑59 19951895
    [Google Scholar]
  34. Omura T. Future perception in P450 research. J. Inorg. Biochem. 2018 186 264 266 10.1016/j.jinorgbio.2018.06.002 29990750
    [Google Scholar]
  35. Paper F.C. M12: Drug interaction studies. Ich. 2019 41 17 19
    [Google Scholar]
  36. Deodhar M. Al Rihani S.B. Arwood M.J. Darakjian L. Dow P. Turgeon J. Michaud V. Mechanisms of cyp450 inhibition: Understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics 2020 12 9 846 10.3390/pharmaceutics12090846 32899642
    [Google Scholar]
  37. Fravel M.A. Ernst M. Drug interactions with antihypertensives. Curr. Hypertens. Rep. 2021 23 3 14 10.1007/s11906‑021‑01131‑y 33666764
    [Google Scholar]
  38. Zhou S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 2008 9 4 310 322 10.2174/138920008784220664 18473749
    [Google Scholar]
  39. Pandian B.A. Sathishraj R. Djanaguiraman M. Prasad P.V.V. Jugulam M. Role of cytochrome P450 enzymes in plant stress response. Antioxidants 2020 9 5 454 10.3390/antiox9050454 32466087
    [Google Scholar]
  40. Gougis P. Hilmi M. Geraud A. Mir O. Funck-Brentano C. Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments. Crit. Rev. Oncol. Hematol. 2021 166 103342 10.1016/j.critrevonc.2021.103342 33930533
    [Google Scholar]
  41. Chakraborty P. Biswas A. Dey S. Bhattacharjee T. Chakrabarty S. Cytochrome P450 gene families: Role in plant secondary metabolites production and plant defense. J. Xenobiot. 2023 13 3 402 423 10.3390/jox13030026 37606423
    [Google Scholar]
  42. Rizzo P. Altschmied L. Ravindran B.M. Rutten T. D’Auria J.C. The biochemical and genetic basis for the biosynthesis of bioactive compounds in hypericum perforatum L., one of the largest medicinal crops in Europe. Genes 2020 11 10 1210 10.3390/genes11101210 33081197
    [Google Scholar]
  43. Shakya P. Marslin G. Siram K. Beerhues L. Franklin G. Elicitation as a tool to improve the profiles of high-value secondary metabolites and pharmacological properties of Hypericum perforatum. J. Pharm. Pharmacol. 2019 71 1 70 82 10.1111/jphp.12743 28523644
    [Google Scholar]
  44. Sotirova Y. Ivanova N. Ermenlieva N. Vilhelmova-Ilieva N. Simeonova L. Metodiev M. Gugleva V. Andonova V. Antimicrobial and antiherpetic properties of nanoencapsulated Hypericum perforatum extract. Pharmaceuticals 2025 18 3 366 10.3390/ph18030366 40143142
    [Google Scholar]
  45. Adiwidjaja J. Boddy A.V. McLachlan A.J. Physiologically based pharmacokinetic modelling of hyperforin to predict drug interactions with St John’s Wort. Clin. Pharmacokinet. 2019 58 7 911 926 10.1007/s40262‑019‑00736‑6 30675694
    [Google Scholar]
  46. Awortwe C. Bruckmueller H. Cascorbi I. Interaction of herbal products with prescribed medications: A systematic review and meta-analysis. Pharmacol. Res. 2019 141 397 408 10.1016/j.phrs.2019.01.028 30660822
    [Google Scholar]
  47. Berry-Bibee E.N. Kim M.J. Tepper N.K. Riley H.E.M. Curtis K.M. Co-administration of St. John’s wort and hormonal contraceptives: A systematic review. Contraception 2016 94 6 668 677 10.1016/j.contraception.2016.07.010 27444983
    [Google Scholar]
  48. Fasinu P.S. Rapp G.K. Herbal interaction with chemotherapeutic drugs—a focus on clinically significant findings. Front. Oncol. 2019 9 1356 10.3389/fonc.2019.01356 31850232
    [Google Scholar]
  49. Soleymani S. Bahramsoltani R. Rahimi R. Abdollahi M. Clinical risks of St John’s Wort (Hypericum perforatum) co-administration. Expert Opin. Drug Metab. Toxicol. 2017 13 10 1047 1062 10.1080/17425255.2017.1378342 28885074
    [Google Scholar]
  50. Chrubasik-Hausmann S. Vlachojannis J. McLachlan A.J. Understanding drug interactions with St John’s wort (Hypericum perforatum L.): Impact of hyperforin content. J. Pharm. Pharmacol. 2019 71 1 129 138 10.1111/jphp.12858 29411879
    [Google Scholar]
  51. Hyperici herba (St. John’s Wort). 2018 Available from: https://www.escop.com/downloads/hypericum-2018/
  52. Wanwimolruk S. Phopin K. Prachayasittikul V. Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). EXCLI J. 2014 13 869 896 26417310
    [Google Scholar]
  53. Ngan C.H. Beglov D. Rudnitskaya A.N. Kozakov D. Waxman D.J. Vajda S. The structural basis of pregnane X receptor binding promiscuity. Biochemistry 2009 48 48 11572 11581 10.1021/bi901578n 19856963
    [Google Scholar]
  54. Rombolà L. Scuteri D. Marilisa S. Watanabe C. Morrone L.A. Bagetta G. Corasaniti M.T. Pharmacokinetic interactions between herbal medicines and drugs: Their mechanisms and clinical relevance. Life 2020 10 7 106 10.3390/life10070106 32635538
    [Google Scholar]
  55. Jiang Y. Zhou Y. Song S. Fan S. Gao Y. Li Y. Huang M. Bi H. St. John’s wort exacerbates acetaminophen-induced liver injury by activation of PXR and CYP-mediated bioactivation. Toxicol. Sci. 2022 190 1 54 63 10.1093/toxsci/kfac094 36073954
    [Google Scholar]
  56. Markert C. Kastner I.M. Hellwig R. Kalafut P. Schweizer Y. Hoffmann M.M. Burhenne J. Weiss J. Mikus G. Haefeli W.E. The effect of induction of CYP3A4 by St John’s wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic Clin. Pharmacol. Toxicol. 2015 116 5 423 428 10.1111/bcpt.12332 25286744
    [Google Scholar]
  57. Hohmann N. Friedrichs A.S. Burhenne J. Blank A. Mikus G. Haefeli W.E. Dose-dependent induction of CYP3A activity by St. John’s wort alone and in combination with rifampin. Clin. Transl. Sci. 2024 17 8 70007 10.1111/cts.70007 39152679
    [Google Scholar]
  58. Dauncey E.A. Irving J.T.W. Allkin R. A review of issues of nomenclature and taxonomy of Hypericum perforatum L. and Kew’s Medicinal Plant Names Services. J. Pharm. Pharmacol. 2019 71 1 4 14 10.1111/jphp.12831 29034955
    [Google Scholar]
  59. Loughren M.J. Kharasch E.D. Kelton-Rehkopf M.C. Syrjala K.L. Shen D.D. Influence of St. John’s wort on intravenous fentanyl pharmacokinetics, pharmacodynamics, and clinical effects. Anesthesiology 2020 132 3 491 503 10.1097/ALN.0000000000003065 31794512
    [Google Scholar]
  60. Zhang S. Jiang L. Che F. Lu Y. Xie Z. Wang H. Arctigenin attenuates ischemic stroke via SIRT1-dependent inhibition of NLRP3 inflammasome. Biochem. Biophys. Res. Commun. 2017 493 1 821 826 10.1016/j.bbrc.2017.08.062 28888980
    [Google Scholar]
  61. Zahner C. Kruttschnitt E. Uricher J. Lissy M. Hirsch M. Nicolussi S. Krähenbühl S. Drewe J. No Clinically Relevant Interactions of St. John’s Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P-glycoprotein. Clin. Pharmacol. Ther. 2019 106 2 432 440 10.1002/cpt.1392 30739325
    [Google Scholar]
  62. Orzetti S. Baldo P. Toxicity derived from interaction between natural compounds and cancer therapeutic drugs metabolized by cyp3a4: Lessons learned from two clinical case reports. Int. J. Mol. Sci. 2023 24 21 15976 10.3390/ijms242115976 37958959
    [Google Scholar]
  63. Sienkiewicz J. Czarnik-Matusewicz H. Wiela-Hojeńska A. Phytotherapy threats with emphasis on St. John's wort medicines. Polish Med. J. 2013 35 309 312 24575655
    [Google Scholar]
  64. Miedziaszczyk M. Bajon A. Jakielska E. Primke M. Sikora J. Skowrońska D. Idasiak-Piechocka I. Controversial interactions of tacrolimus with dietary supplements, herbs and food. Pharmaceutics 2022 14 10 2154 10.3390/pharmaceutics14102154 36297591
    [Google Scholar]
  65. Stolbach A. Paziana K. Heverling H. Pham P. A review of the toxicity of hiv medications ii: Interactions with drugs and complementary and alternative medicine products. J. Med. Toxicol. 2015 11 3 326 341 10.1007/s13181‑015‑0465‑0 26036354
    [Google Scholar]
  66. Grimstein M. Huang S.M. A regulatory science viewpoint on botanical-drug interactions. Yao Wu Shi Pin Fen Xi 2018 26 2S S12 S25 29703380
    [Google Scholar]
  67. Amjadi I. Mohajeri M. Borisov A. Hosseini M.S. Antiproliferative effects of free and encapsulated Hypericum Perforatum L. extract and its potential interaction with doxorubicin for esophageal squamous cell carcinoma. J. Pharmacopuncture 2019 22 2 102 108 10.3831/KPI.2019.22.013 31338250
    [Google Scholar]
  68. Goey A.K.L. Meijerman I. Rosing H. Marchetti S. Mergui-Roelvink M. Keessen M. Burgers J.A. Beijnen J.H. Schellens J.H.M. The effect of St John’s wort on the pharmacokinetics of docetaxel. Clin. Pharmacokinet. 2014 53 1 103 110 10.1007/s40262‑013‑0102‑5 24068654
    [Google Scholar]
  69. Gümüs K.S. Teegelbekkers A. Sauter M. Meid A.D. Burhenne J. Weiss J. Blank A. Haefeli W.E. Czock D. Effect of tacrolimus formulation (Prolonged-Release vs immediate-release) on its susceptibility to drug-drug interactions with St. John’s Wort. Clin. Pharmacol. Drug Dev. 2024 13 3 297 306 10.1002/cpdd.1364 38176912
    [Google Scholar]
  70. Hohmann N. Maus A. Carls A. Haefeli W.E. Mikus G. St. John’s wort treatment in women bears risks beyond pharmacokinetic drug interactions. Arch. Toxicol. 2016 90 4 1013 1015 10.1007/s00204‑015‑1532‑7 25963330
    [Google Scholar]
  71. Huppertz A. Werntz L. Meid A.D. Foerster K.I. Burhenne J. Czock D. Mikus G. Haefeli W.E. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John’s wort should be avoided. Br. J. Clin. Pharmacol. 2018 84 12 2903 2913 10.1111/bcp.13757 30192025
    [Google Scholar]
  72. Stage T.B. Pedersen R.S. Damkier P. Christensen M.M.H. Feddersen S. Larsen J.T. Højlund K. Brøsen K. Intake of St John’s wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. Br. J. Clin. Pharmacol. 2015 79 2 298 306 10.1111/bcp.12510 25223504
    [Google Scholar]
  73. Awortwe C. Makiwane M. Reuter H. Muller C. Louw J. Rosenkranz B. Critical evaluation of causality assessment of herb–drug interactions in patients. Br. J. Clin. Pharmacol. 2018 84 4 679 693 10.1111/bcp.13490 29363155
    [Google Scholar]
  74. Ng J.Y. Munford V. Thakar H. Web-based online resources about adverse interactions or side effects associated with complementary and alternative medicine: A systematic review, summarization and quality assessment. BMC Med. Inform. Decis. Mak. 2020 20 1 290 10.1186/s12911‑020‑01298‑5 33167980
    [Google Scholar]
  75. Babos M. Heinan M. Redmond L. Moiz F. Souza-Peres J. Samuels V. Masimukku T. Hamilton D. Khalid M. Herscu P. Herb–drug interactions: Worlds intersect with the patient at the center. Medicines 2021 8 8 44 10.3390/medicines8080044 34436223
    [Google Scholar]
  76. Harnett J. McIntyre E. Adams J. Addison T. Bannerman H. Egelton L. Ma J. Zabakly L. Steel A. Prevalence and characteristics of australians’ complementary medicine product use, and concurrent use with prescription and over-the-counter medications—a cross sectional study. Nutrients 2023 15 2 327 10.3390/nu15020327 36678198
    [Google Scholar]
  77. Zuo H.L. Huang H.Y. Lin Y.C.D. Cai X.X. Kong X.J. Luo D.L. Zhou Y.H. Huang H.D. Enzyme activity of natural products on cytochrome P450. Molecules 2022 27 2 515 10.3390/molecules27020515 35056827
    [Google Scholar]
  78. St. John’s wort - Mayo clinic. 2013 Available from: https://www.mayoclinic.org/drugs-supplements-st-johns- wort/art-20362212
  79. Trana C. Toth G. Wijns W. Barbato E. St. John’s Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: A single-center randomized open-label trial (St. John’s Trial). J. Cardiovasc. Transl. Res. 2013 6 3 411 414 10.1007/s12265‑013‑9455‑2 23463297
    [Google Scholar]
  80. Gong L. Zhang C.M. Lv J.F. Zhou H.H. Fan L. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet. Genomics 2017 27 9 337 346 10.1097/FPC.0000000000000297 28731962
    [Google Scholar]
  81. Liu J. Lu Y.F. Corton J.C. Klaassen C.D. Expression of cytochrome P450 isozyme transcripts and activities in human livers. Xenobiotica 2021 51 3 279 286 10.1080/00498254.2020.1867929 33350342
    [Google Scholar]
  82. Liu Y. Li J. Wang T. Wang Y. Zhao L. Fang Y. The effect of genistein on glucose control and insulin sensitivity in postmenopausal women: A meta-analysis. Maturitas 2017 97 44 52 10.1016/j.maturitas.2016.12.004 28159061
    [Google Scholar]
  83. Schäfer A.M. Rysz M.A. Schädeli J. Hübscher M. Khosravi H. Fehr M. Seibert I. Potterat O. Smieško M. Meyer zu Schwabedissen H.E. St. John’s wort formulations induce rat CYP3A23-3A1 independent of their hyperforin content. Mol. Pharmacol. 2024 105 1 14 22 10.1124/molpharm.123.000725 37863663
    [Google Scholar]
  84. Gu D. Wang H. Yan M. Li Y. Yang S. Shi D. Guo S. Wu L. Liu C. Echinacea purpurea (L.) Moench extract suppresses inflammation by inhibition of C3a/C3aR signaling pathway in TNBS-induced ulcerative colitis rats. J. Ethnopharmacol. 2023 307 116221 10.1016/j.jep.2023.116221 36754188
    [Google Scholar]
  85. Burlou-Nagy C. Bănică F. Jurca T. Vicaș L.G. Marian E. Muresan M.E. Bácskay I. Kiss R. Fehér P. Pallag A. Echinacea purpurea (L.) Moench: Biological and pharmacological properties. a review. Plants 2022 11 9 1244 10.3390/plants11091244 35567246
    [Google Scholar]
  86. Gasmi A. Mujawdiya P.K. Noor S. Lysiuk R. Darmohray R. Piscopo S. Lenchyk L. Antonyak H. Dehtiarova K. Shanaida M. Polishchuk A. Shanaida V. Peana M. Bjørklund G. Polyphenols in metabolic diseases. Molecules 2022 27 19 6280 10.3390/molecules27196280 36234817
    [Google Scholar]
  87. Awortwe C. Manda V.K. Avonto C. Khan S.I. Khan I.A. Walker L.A. Bouic P.J. Rosenkranz B. Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway. Xenobiotica 2015 45 3 218 229 10.3109/00498254.2014.973930 25377539
    [Google Scholar]
  88. Hogle B.C. Guan X. Folan M.M. Xie W. PXR as a mediator of herb-drug interaction. Yao Wu Shi Pin Fen Xi 2018 26 2S S26 S31 29703383
    [Google Scholar]
  89. Matura J.M. Shea L.A. Bankes V.A. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations. Ir. J. Med. Sci. 2022 191 5 2357 2365 10.1007/s11845‑021‑02828‑4 34734388
    [Google Scholar]
  90. Hunter J. Harnett J.E. Interactions between complementary medicines and drugs used in primary care and oral COVID-19 antiviral drugs. Aust. J. Gen. Pract. 2023 52 6 345 357 10.31128/AJGP‑12‑22‑6631 37291812
    [Google Scholar]
  91. Manthalkar L. Ajazuddin Bhattacharya S. Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs. Discov. Oncol. 2022 13 1 142 10.1007/s12672‑022‑00605‑y 36571647
    [Google Scholar]
  92. Drozdoff L. Klein E. Kalder M. Brambs C. Kiechle M. Paepke D. Potential interactions of biologically based complementary medicine in gynecological oncology. Integr. Cancer Ther. 2019 18 1534735419846392 10.1177/1534735419846392 31046491
    [Google Scholar]
  93. Tian J. Liu Y. Chen K. Ginkgo biloba extract in vascular protection: Molecular mechanisms and clinical applications. Curr. Vasc. Pharmacol. 2017 15 6 532 548 28707602
    [Google Scholar]
  94. Mohanta T.K. Tamboli Y. Zubaidha P.K. Phytochemical and medicinal importance of Ginkgo biloba L. Nat. Prod. Res. 2014 28 10 746 752 10.1080/14786419.2013.879303 24499319
    [Google Scholar]
  95. Wang C Zhang W Liao Y Ye J Xu F Wang Q. Ginkgo biloba flavonoids: Analysis of functions, regulatory mechanisms, and extraction. Plant Biol 2025 27 6 962 974 10.1111/plb.70054
    [Google Scholar]
  96. Tatlı Çankaya Iİ Devkota HP Zengin G Šamec D Neuroprotective potential of biflavone ginkgetin: A review. Life 2023 13 2 562 10.3390/life13020562 36836918
    [Google Scholar]
  97. Lu J. Xie L. Liu K. Zhang X. Wang X. Dai X. Liang Y. Cao Y. Li X. Bilobalide: A review of its pharmacology, pharmacokinetics, toxicity, and safety. Phytother. Res. 2021 35 11 6114 6130 10.1002/ptr.7220 34342079
    [Google Scholar]
  98. Sanjai K.S. Purushothaman A. Warfarin interactions with complementary medicines, herbs and dietary supplements. 2015 Available from: www.jocpr.com
  99. Choi J.G. Eom S.M. Kim J. Kim S.H. Huh E. Kim H. Lee Y. Lee H. Oh M.S. A comprehensive review of recent studies on herb-drug interaction: A focus on pharmacodynamic interaction. J. Altern. Complement. Med. 2016 22 4 262 279 10.1089/acm.2015.0235 27003511
    [Google Scholar]
  100. Wilson V. Maulik S.K. Herb-drug interactions in neurological disorders: A critical appraisal. Curr. Drug Metab. 2018 19 5 443 453 10.2174/1389200218666171031123738 29086684
    [Google Scholar]
  101. Cheng W. Xia K. Wu S. Li Y. Herb-drug interactions and their impact on pharmacokinetics: An update. Curr. Drug Metab. 2023 24 1 28 69 10.2174/1389200224666230116113240 36650621
    [Google Scholar]
  102. Wei Y. Tang C. Sant V. Li S. Poloyac S.M. Xie W. A molecular aspect in the regulation of drug metabolism: Does pxr-induced enzyme expression always lead to functional changes in drug metabolism? Curr. Pharmacol. Rep. 2016 2 4 187 192 10.1007/s40495‑016‑0062‑1 27795941
    [Google Scholar]
  103. Alzubaidi F.A. Hussain S.A. Effects of Ginkgo biloba extract on the oral bioavailability of fluoxetine and venlafaxine in rats. Am. J. Pharmacol. Sci. 2015 3 7 12
    [Google Scholar]
  104. Le T.T. McGrath S.R. Fasinu P.S. Herb-drug interactions in neuropsychiatric pharmacotherapy – A review of clinically relevant findings. Curr. Neuropharmacol. 2022 20 9 1736 1751 10.2174/1570159X19666210809100357 34370637
    [Google Scholar]
  105. Wang R. Zhang H. Wang Y. Yu X. Yuan Y. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9. J. Ethnopharmacol. 2016 180 87 96 10.1016/j.jep.2016.01.021 26806573
    [Google Scholar]
  106. Wang B. Shi C. Feng L. Pan W. Tian X.G. Sun C.P. Wang C. Ning J. Lv X. Wang Y. Yuan Q.H. Guan R.X. Zhang H.L. Ma X.C. Ma T.H. Potent inhibition of human cytochrome p450 3a4 by biflavone components from ginkgo biloba and selaginella tamariscina. Front. Pharmacol. 2022 13 856784 10.3389/fphar.2022.856784 35295338
    [Google Scholar]
  107. Ong C.E. Muthiah Y.D. Sulaiman S. Ismail R. Inhibition of human cytochrome p450 2c8-catalyzed amodiaquine n-desethylation: Effect of five traditionally and commonly used herbs. Pharmacognosy Res. 2016 8 4 292 297 10.4103/0974‑8490.188886 27695271
    [Google Scholar]
  108. Ji H. Zhang G. Yue F. Zhou X. Adverse event due to a likely interaction between sodium aescinate and ginkgo biloba extract: A case report. J. Clin. Pharm. Ther. 2017 42 2 237 238 10.1111/jcpt.12500 28144968
    [Google Scholar]
  109. Zhang Y. Miao L. Lin L. Ren C.Y. Liu J.X. Cui Y.M. Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats. Phytomedicine 2018 38 125 134 10.1016/j.phymed.2017.02.007 29425645
    [Google Scholar]
  110. Xing X. Kong M. Hou Q. Li J. Qian W. Chen X. Li H. Yang C. Effects of ginkgo leaf tablet on the pharmacokinetics of rosiglitazone in rats and its potential mechanism. Pharm. Biol. 2022 60 1 1190 1197 10.1080/13880209.2022.2087688 35758248
    [Google Scholar]
  111. Zhou X. Ma Z. Geng T. Wang Z. Ding G. Yu-an B. Xiao W. Evaluation of in vitro inhibition and induction of cytochrome P450 activities by hydrolyzed ginkgolides. J. Ethnopharmacol. 2014 158 Pt A 132 139 10.1016/j.jep.2014.10.023 25456428
    [Google Scholar]
  112. Deng Y. Mo Y. Chen X. Zhang L. Liao C. Song Y. Xu C. Effect of ginkgo biloba extract on the pharmacokinetics and metabolism of clopidogrel in rats. Phytother. Res. 2016 30 11 1886 1892 10.1002/ptr.5691 27487816
    [Google Scholar]
  113. Shao F. Zhang H. Xie L. Chen J. Zhou S. Zhang J. Lv J. Hao W. Ma Y. Liu Y. Ou N. Xiao W. Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. Eur. J. Clin. Pharmacol. 2017 73 5 537 546 10.1007/s00228‑017‑2197‑3 28105513
    [Google Scholar]
  114. Zadoyan G. Rokitta D. Klement S. Dienel A. Hoerr R. Gramatté T. Fuhr U. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: A cocktail interaction study in healthy volunteers. Eur. J. Clin. Pharmacol. 2012 68 5 553 560 10.1007/s00228‑011‑1174‑5 22189672
    [Google Scholar]
  115. Su C.Y. Ming Q.L. Rahman K. Han T. Qin L.P. Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Chin. J. Nat. Med. 2015 13 3 163 182 10.1016/S1875‑5364(15)30002‑9 25835361
    [Google Scholar]
  116. Liang W. Chen W. Wu L. Li S. Qi Q. Cui Y. Liang L. Ye T. Zhang L. Quality evaluation and chemical markers screening of salvia miltiorrhiza Bge. (Danshen) based on HPLC fingerprints and HPLC-MSn coupled with chemometrics. Molecules 2017 22 3 478 10.3390/molecules22030478 28304365
    [Google Scholar]
  117. Akaberi M Iranshahi M Mehri S. Molecular signaling pathways behind the biological effects of salvia species diterpenes in neuropharmacology and cardiology. Phytother Res 2016 30 6 878 93 10.1002/ptr.5599
    [Google Scholar]
  118. Zhumaliyeva G. Zhussupova A. Zhusupova G.E. Błońska-Sikora E. Cerreto A. Omirbekova N. Zhunusbayeva Z. Gemejiyeva N. Ramazanova M. Wrzosek M. Ross S.A. Natural Compounds of Salvia L. Biomedicines 2023 11 12 3151 10.3390/biomedicines11123151 38137372
    [Google Scholar]
  119. Sun S. Wang R. Fan J. Zhang G. Zhang H. Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. Pharm. Biol. 2018 56 1 104 108 10.1080/13880209.2018.1424209 29322864
    [Google Scholar]
  120. Zhang H. Han X. Li Y. Li H. Guo X. Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. Pharm. Biol. 2019 57 1 306 309 10.1080/13880209.2019.1604768 31060428
    [Google Scholar]
  121. zhang X. Ma Z. Liang Q. Tang X. Hu D. Liu C. Tan H. Xiao C. Zhang B. Wang Y. Gao Y. Tanshinone IIA exerts protective effects in a LCA-induced cholestatic liver model associated with participation of pregnane X receptor. J. Ethnopharmacol. 2015 164 357 367 10.1016/j.jep.2015.01.047 25660334
    [Google Scholar]
  122. Wang X. Fa J. Zhang Y. Huang S. Liu J. Gao J. Xing L. Liu Z. Wang X. Evaluation of herb–drug interaction between danshen and rivaroxaban in rat and human liver microsomes. Front. Pharmacol. 2022 13 950525 10.3389/fphar.2022.950525 35928264
    [Google Scholar]
  123. Wang X. Ha D. Yoshitake R. Chan Y.S. Sadava D. Chen S. Exploring the biological activity and mechanism of xenoestrogens and phytoestrogens in cancers: Emerging methods and concepts. Int. J. Mol. Sci. 2021 22 16 8798 10.3390/ijms22168798 34445499
    [Google Scholar]
  124. Qiu F. Zhang R. Sun J. A J. Hao H. Peng Y. Ai H. Wang G. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab. Dispos. 2008 36 7 1308 1314 10.1124/dmd.108.021030 18411400
    [Google Scholar]
  125. Chen F. Li L. Tian D.D. Salvia miltiorrhiza roots against cardiovascular disease: Consideration of herb-drug interactions. Biomed. Res. Int. 2017 10.1155/2017/9868694
    [Google Scholar]
  126. Zhou C. Xu M. Yu H. Zheng X.T. Zhong Z.F. Zhang L. Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Food Chem. Toxicol. 2018 119 302 308 10.1016/j.fct.2018.02.051 29496531
    [Google Scholar]
  127. Zhang Z. Wang Y. Tan W. Wang S. Liu J. Liu X. A review of danshen combined with clopidogrel in the treatment of coronary heart disease. Evid. Based Compl. Alter. Med. 2019 2721413 10.1155/2019/2721413
    [Google Scholar]
  128. Ji S. Shao X. Su Z. Ji L. Wang Y. Ma Y. Zhao L. Du Y. Guo M. Tang D. Segmented scan modes and polarity-based LC-MS for pharmacokinetic interaction study between Fufang Danshen Dripping Pill and Clopidogrel Bisulfate Tablet. J. Pharm. Biomed. Anal. 2019 174 367 375 10.1016/j.jpba.2019.05.055 31202879
    [Google Scholar]
  129. Xu MJ Jiang LF Wu T Chu JH Wei YD Aa JY Wang GJ Hao HP Ju WZ Li P Inhibitory effects of danshen components on CYP2C8 and CYP2J2. Chem Biol Interact 2018 289 15 22 10.1016/j.cbi.2018.04.011
    [Google Scholar]
  130. Liu J. Shi Y. Peng D. Wang L. Yu N. Wang G. Salvia miltiorrhiza Bge. (Danshen) in the treating non-alcoholic fatty liver disease based on the regulator of metabolic targets. Front Cardiovasc Med 2022 9 842980 10.3389/fcvm.2022.842980
    [Google Scholar]
  131. Hong M. Li S. Wang N. Tan H.Y. Cheung F. Feng Y. A biomedical investigation of the hepatoprotective effect of radix salviae miltiorrhizae and network pharmacology-based prediction of the active compounds and molecular targets. Int. J. Mol. Sci. 2017 18 3 620 10.3390/ijms18030620 28335383
    [Google Scholar]
  132. Li Y. Wang Q. Jin J. Tan B. Ren J. Song G. Zou B. Weng F. Yan D. Qiu F. 15,16-dihydrotanshinone I in Danshen ethanol extract aggravated cholestasis by inhibiting Cyp3a11 mediated bile acids hydroxylation. Toxicol. Lett. 2023 377 62 70 10.1016/j.toxlet.2023.02.005 36804361
    [Google Scholar]
  133. Zhou X. Cheung C.M. Yang J. Or P.M.Y. Lee W.Y.W. Yeung J.H.K. Danshen (S alvia miltiorrhiza) water extract inhibits paracetamol-induced toxicity in primary rat hepatocytes via reducing CYP2E1 activity and oxidative stress. J. Pharm. Pharmacol. 2015 67 7 980 989 10.1111/jphp.12381 25645193
    [Google Scholar]
  134. Meng L. Li Y. Xue C. Ding C. Wang X. Fu R. Li Y. Li X. Dong Z. Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. J. Pharm. Biomed. Anal. 2021 195 113887 10.1016/j.jpba.2020.113887 33418444
    [Google Scholar]
  135. Alehaideb Z. Sheriffdeen M. Law F.C.P. Inhibition of caffeine metabolism by Apiaceous and Rutaceae families of plant products in humans: in vivo and in vitro studies. Front. Pharmacol. 2021 12 641090 10.3389/fphar.2021.641090 33995046
    [Google Scholar]
  136. Zhang J.X. Qi M.J. Shi M.Z. Chen J.J. Zhang X.Q. Yang J. Zhang K.Z. Han Y.L. Guo C. Effects of Danhong injection, a traditional Chinese medicine, on nine cytochrome P450 isoforms in vitro. Biomed. Chromatogr. 2019 33 4 4454 10.1002/bmc.4454 30520061
    [Google Scholar]
  137. Song M. Sheng X. Zhang J. Li X. Dai Q. Chen Y. Kang A. Homeostatic regulation of the aryl hydrocarbon receptor-cytochrome P450 1a axis by Scutellaria baicalensis-Coptis chinensis herb pair and its main constituents. J. Ethnopharmacol. 2022 297 115545 10.1016/j.jep.2022.115545 35843411
    [Google Scholar]
  138. Rauf A. Abu-Izneid T. Thiruvengadam M. Imran M. Olatunde A. Shariati M.A. Bawazeer S. Naz S. Shirooie S. Sanches-Silva A. Farooq U. Kazhybayeva G. Garlic (Allium sativum L.): Its chemistry, nutritional composition, toxicity, and anticancer properties. Curr. Top. Med. Chem. 2022 22 11 957 972 10.2174/1568026621666211105094939 34749610
    [Google Scholar]
  139. Miki S. Takashima M. Suzuki J-I. Anti-atherosclerotic effect of aged garlic extract: Mode of action and therapeutic benefits (Review). Exp. Ther. Med 2025 29 5 104 10.3892/etm.2025.12854
    [Google Scholar]
  140. Gasmi A. Shanaida M. Oleshchuk O. Semenova Y. Mujawdiya P.K. Ivankiv Y. Pokryshko O. Noor S. Piscopo S. Adamiv S. Bjørklund G. Natural ingredients to improve immunity. Pharmaceuticals 2023 16 4 528 10.3390/ph16040528 37111285
    [Google Scholar]
  141. Liu Y. Chen Y. Zhang J. Ran G. Cheng Z. Wang X. Liao Y. Mao X. Peng Y. Li W. Zheng J. Dihydrotanshinone I–induced CYP1 enzyme inhibition and alteration of estradiol metabolism. Drug Metab. Dispos. 2024 52 3 188 197 10.1124/dmd.123.001490 38123940
    [Google Scholar]
  142. Jani A. Mehta A. Mehta A. Mehta A. Pharmacology of allium sativum in relation to cytochrome p450 and possible drug interactions. Pharmacogn. Rev. 2007 1 222 226
    [Google Scholar]
  143. Lam Y.W.F. Huang S-M. Hall S.D. Herbal supplements-drug interactions: Scientific and regulatory perspectives. CRC PRESS 2006 358 Available from: https://scholars.uthscsa.edu/en/publications/herbal-supplements-drug-interactions-scientific-and-regulatory-pe
    [Google Scholar]
  144. Hermann R. von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 2012 78 13 1458 1477 10.1055/s‑0032‑1315117 22855269
    [Google Scholar]
  145. Greenblatt D.J. Leigh-Pemberton R.A. von Moltke L.L. in vitro interactions of water-soluble garlic components with human cytochromes p450. J. Nutr. 2006 136 3 806S 809S 10.1093/jn/136.3.806S 16484569
    [Google Scholar]
  146. Cho H.J. Yoon I.S. Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein. Evid. Based Complement. Alternat. Med. 2015 2015 1 10 10.1155/2015/736431 25632290
    [Google Scholar]
  147. Teyssier C. Guenot L. Suschetet M. Siess M.H. Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases. Drug Metab. Dispos. 1999 27 7 835 841 10.1016/S0090‑9556(24)11821‑1 10383929
    [Google Scholar]
  148. Kishimoto R. Ueda M. Yoshinaga H. Goda K. Park S.S. Combined effects of ethanol and garlic on hepatic ethanol metabolism in mice. J. Nutr. Sci. Vitaminol. 1999 45 3 275 286 10.3177/jnsv.45.275 10524347
    [Google Scholar]
  149. Davenport D.M. Wargovich M.J. Modulation of cytochrome P450 enzymes by organosulfur compounds from garlic. Food Chem. Toxicol. 2005 43 12 1753 1762 10.1016/j.fct.2005.05.018 16000231
    [Google Scholar]
  150. Sharifi-Rad J. Silva N.C.C. Jantwal A. Bhatt I.D. Sharopov F. Cho W.C. Therapeutic potential of allicin-rich garlic preparations: Emphasis on clinical evidence toward upcoming drugs formulation. Appl. Sci. 2019 9 5555 10.3390/app9245555
    [Google Scholar]
  151. Choi S. Oh D.S. Jerng U.M. A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin. PLoS One 2017 12 8 0182794 10.1371/journal.pone.0182794 28797065
    [Google Scholar]
  152. Hajda J. Rentsch K.M. Gubler C. Steinert H. Stieger B. Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur. J. Pharm. Sci. 2010 41 5 729 735 10.1016/j.ejps.2010.09.016 20933082
    [Google Scholar]
  153. Mohammed Abdul M.I. Jiang X. Williams K.M. Day R.O. Roufogalis B.D. Liauw W.S. Xu H. McLachlan A.J. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br. J. Pharmacol. 2008 154 8 1691 1700 10.1038/bjp.2008.210 18516070
    [Google Scholar]
  154. Borek C. Garlic supplements and saquinavir. Clin. Infect. Dis. 2002 35 3 343 343 10.1086/340987 12115105
    [Google Scholar]
  155. Lai W. Yang S. Lin X. Zhang X. Huang Y. Zhou J. Fu C. Li R. Zhang Z. Zingiber officinale : A systematic review of botany, phytochemistry and pharmacology of gut microbiota-related gastrointestinal benefits. Am. J. Chin. Med. 2022 50 4 1007 1042 10.1142/S0192415X22500410 35729087
    [Google Scholar]
  156. Zhang M. Zhao R. Wang D. Wang L. Zhang Q. Wei S. Lu F. Peng W. Wu C. Ginger (Zingiber officinale Rosc.) and its bioactive components are potential resources for health beneficial agents. Phytother. Res. 2021 35 2 711 742 10.1002/ptr.6858 32954562
    [Google Scholar]
  157. Lu F. Cai H. Li S. Xie W. Sun R. The chemical signatures of water extract of Zingiber officinale Rosc. Molecules 2022 27 22 7818 10.3390/molecules27227818 36431919
    [Google Scholar]
  158. Shaukat M.N. Nazir A. Fallico B. Nouman Shaukat M. Nazir A. Fallico B. Ginger bioactives: A comprehensive review of health benefits and potential food applications. Antioxidants 2023 12 11 2015 10.3390/antiox12112015 38001868
    [Google Scholar]
  159. Sharma S. Shukla M.K. Sharma K.C. Tirath Kumar L. Anal J.M.H. Upadhyay S.K. Bhattacharyya S. Kumar D. Revisiting the therapeutic potential of gingerols against different pharmacological activities. Naunyn Schmiedebergs Arch. Pharmacol. 2023 396 4 633 647 10.1007/s00210‑022‑02372‑7 36585999
    [Google Scholar]
  160. Dugasani S. Pichika M.R. Nadarajah V.D. Balijepalli M.K. Tandra S. Korlakunta J.N. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J. Ethnopharmacol. 2010 127 2 515 520 10.1016/j.jep.2009.10.004 19833188
    [Google Scholar]
  161. Yücel Ç. Karatoprak G.Ş. Açıkara Ö.B. Akkol E.K. Barak T.H. Sobarzo-Sánchez E. Aschner M. Shirooie S. Immunomodulatory and anti-inflammatory therapeutic potential of gingerols and their nanoformulations. Front. Pharmacol. 2022 13 902551 10.3389/fphar.2022.902551 36133811
    [Google Scholar]
  162. Park M. Bae J. Lee D.S. Antibacterial activity of [10]-gingerol and [12]-gingerol isolated from ginger rhizome against periodontal bacteria. Phytother. Res. 2008 22 11 1446 1449 10.1002/ptr.2473 18814211
    [Google Scholar]
  163. Qiu J.X. Zhou Z.W. He Z.X. Zhang X. Zhou S.F. Zhu S. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies. Drug Des. Devel. Ther. 2015 9 841 866 25733806
    [Google Scholar]
  164. Husain I. Dale O.R. Idrisi M. Gurley B.J. Avula B. Katragunta K. Ali Z. Chittiboyina A. Noonan G. Khan I.A. Khan S.I. Evaluation of the herb–drug interaction (HDI) potential of Zingiber officinale and its major phytoconstituents. J. Agric. Food Chem. 2023 71 19 7521 7534 10.1021/acs.jafc.2c07912 37134183
    [Google Scholar]
  165. Yoshida K. Satsu H. Mikubo A. Ogiwara H. Yakabe T. Inakuma T. Shimizu M. 6-shogaol, a major compound in ginger, induces aryl hydrocarbon receptor-mediated transcriptional activity and gene expression. J. Agric. Food Chem. 2014 62 24 5492 5499 10.1021/jf405146j 24857157
    [Google Scholar]
  166. Mahdavi S. Palatini P. El-Sohemy A. CYP1A2 genetic variation, coffee intake, and kidney dysfunction. JAMA Netw. Open 2023 6 1 e2247868 e2247868 10.1001/jamanetworkopen.2022.47868 36701157
    [Google Scholar]
  167. Mukkavilli R. Gundala S.R. Yang C. Donthamsetty S. Cantuaria G. Jadhav G.R. Vangala S. Reid M.D. Aneja R. Modulation of cytochrome P450 metabolism and transport across intestinal epithelial barrier by ginger biophenolics. PLoS One 2014 9 9 108386 10.1371/journal.pone.0108386 25251219
    [Google Scholar]
  168. Kim I.S. Kim S.Y. Yoo H.H. Effects of an aqueous-ethanolic extract of ginger on cytochrome P450 enzyme-mediated drug metabolism. Pharmazie 2012 67 12 1007 1009 23346764
    [Google Scholar]
  169. Mao Q.Q. Xu X.Y. Cao S.Y. Gan R.Y. Corke H. Beta T. Li H.B. Bioactive compounds and bioactivities of ginger (zingiber officinale roscoe). Foods 2019 8 6 185 10.3390/foods8060185 31151279
    [Google Scholar]
  170. Tajmohammadi A. Razavi B.M. Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review. Phytother. Res. 2018 32 10 1933 1949 10.1002/ptr.6153 30015401
    [Google Scholar]
  171. Bijak M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)—Chemistry, bioavailability, and metabolism. Molecules 2017 22 11 1942 10.3390/molecules22111942 29125572
    [Google Scholar]
  172. Wu X. Chen J. Ping K. Xia Y. Li M. Xiang Y. Feng H. Dong J. Silybin mitigated liver and brain damage after difenoconazole exposure: Crosstalk between oxidative stress, inflammation, ferroptosis and apoptosis. Pestic. Biochem. Physiol. 2024 202 105942 10.1016/j.pestbp.2024.105942 38879300
    [Google Scholar]
  173. Shahsavari K. Ardekani S.S. Ardekani M.R.S. Esfahani M.M. Kazemizadeh H. Jamialahmadi T. Iranshahi M. Khanavi M. Hasanpour M. Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury. BMC Complementary Medicine and Therapies 2025 25 1 134 10.1186/s12906‑025‑04886‑y 40221681
    [Google Scholar]
  174. Zhang X. Liu M. Wang Z. Wang P. Kong L. Wu J. Wu W. Ma L. Jiang S. Ren W. Du L. Ma W. Liu X. A review of the botany, phytochemistry, pharmacology, synthetic biology and comprehensive utilization of Silybum marianum. Front. Pharmacol. 2024 15 1417655 10.3389/fphar.2024.1417655 39055491
    [Google Scholar]
  175. Liu Y. Yu Q. Chen Y. Effect of silibinin on CFLAR-JNK pathway in oleic acid-treated HepG2 cells. Biomed. Pharmacother. 2018 108 716 723 10.1016/j.biopha.2018.09.089 30248539
    [Google Scholar]
  176. Faisal Z. Mohos V. Fliszár-Nyúl E. Valentová K. Káňová K. Lemli B. Kunsági-Máté S. Poór M. Interaction of silymarin components and their sulfate metabolites with human serum albumin and cytochrome P450 (2C9, 2C19, 2D6, and 3A4) enzymes. Biomed. Pharmacother. 2021 138 111459 10.1016/j.biopha.2021.111459 33706132
    [Google Scholar]
  177. Mooiman K.D. Maas-Bakker R.F. Moret E.E. Beijnen J.H. Schellens J.H.M. Meijerman I. Milk thistle’s active components silybin and isosilybin: Novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metab. Dispos. 2013 41 8 1494 1504 10.1124/dmd.113.050971 23674609
    [Google Scholar]
  178. Albassam A.A. Frye R.F. Markowitz J.S. The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes. Chem. Biol. Interact. 2017 271 24 29 10.1016/j.cbi.2017.04.025 28457856
    [Google Scholar]
  179. Jančová P. Anzenbacherová E. Papoušková B. Lemr K. Lužná P. Veinlichová A. Anzenbacher P. Šimánek V. Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab. Dispos. 2007 35 11 2035 2039 10.1124/dmd.107.016410 17670841
    [Google Scholar]
  180. Hüttl M. Markova I. Miklankova D. Zapletalova I. Poruba M. Racova Z. Vecera R. Malinska H. The beneficial additive effect of silymarin in metformin therapy of liver steatosis in a pre-diabetic model. Pharmaceutics 2021 14 1 45 10.3390/pharmaceutics14010045 35056941
    [Google Scholar]
  181. Bjørklund G. Cruz-Martins N. Goh B.H. Mykhailenko O. Lysiuk R. Shanaida M. Lenchyk L. Upyr T. Rusu M.E. Pryshlyak A. Shanaida V. Chirumbolo S. Medicinal plant-derived phytochemicals in detoxification. Curr. Pharm. Des. 2024 30 13 988 1015 10.2174/1381612829666230809094242 37559241
    [Google Scholar]
  182. Gufford B.T. Chen G. Lazarus P. Graf T.N. Oberlies N.H. Paine M.F. Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation. Drug Metab. Dispos. 2014 42 10 1675 1683 10.1124/dmd.114.059451 25008344
    [Google Scholar]
  183. Kawaguchi-Suzuki M. Frye R.F. Zhu H.J. Brinda B.J. Chavin K.D. Bernstein H.J. Markowitz J.S. The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metab. Dispos. 2014 42 10 1611 1616 10.1124/dmd.114.057232 25028567
    [Google Scholar]
  184. Bjørklund G. Storchylo O. Butnariu M. Dadar M. Chirumbolo S. Milk thistle (Silybum marianum): Potential role in cancer prevention. Curr. Med. Chem. 2025 32 39 8895 8912 10.2174/0109298673371391250415105506
    [Google Scholar]
  185. Salari S. Amiri M.S. Ramezani M. Moghadam A.T. Elyasi S. Sahebkar A. Emami S.A. Ethnobotany, phytochemistry, traditional and modern uses of Actaea racemosa L. (Black cohosh): A review. Adv. Exp. Med. Biol. 2021 1308 403 449 10.1007/978‑3‑030‑64872‑5_24 33861455
    [Google Scholar]
  186. Zhang Q Wei W Jin X Lu J Chen S Ogaji OD Traditional uses, phytochemistry, pharmacology, quality control and clinical studies of Cimicifugae Rhizoma: A comprehensive review. Chin Med 2024 19 1 66 10.1186/s13020‑024‑00937‑7
    [Google Scholar]
  187. Mohapatra S. Iqubal A. Ansari M.J. Jan B. Zahiruddin S. Mirza M.A. Ahmad S. Iqbal Z. Benefits of black cohosh (Cimicifuga racemosa) for women health: An up-close and in-depth review. Pharmaceuticals 2022 15 3 278 10.3390/ph15030278 35337076
    [Google Scholar]
  188. Muqeet Adnan M. Khan M. Hashmi S. Hamza M. AbdulMujeeb S. Amer S. Black cohosh and liver toxicity: Is there a relationship? Case Rep. Gastrointest. Med. 2014 2014 1 3 10.1155/2014/860614 25093128
    [Google Scholar]
  189. Yu Y. Tan J. Nie J. Lv C. Lu J. Fibrous roots of cimicifuga are at risk of hepatotoxicity. Molecules 2022 27 3 938 10.3390/molecules27030938 35164202
    [Google Scholar]
  190. Borrelli F. Ernst E. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: A systematic review of its efficacy. Pharmacol. Res. 2008 58 1 8 14 10.1016/j.phrs.2008.05.008 18585461
    [Google Scholar]
  191. Fritz H. Seely D. McGowan J. Skidmore B. Fernandes R. Kennedy D.A. Cooley K. Wong R. Sagar S. Balneaves L.G. Fergusson D. Black cohosh and breast cancer: A systematic review. Integr. Cancer Ther. 2014 13 1 12 29 10.1177/1534735413477191 23439657
    [Google Scholar]
  192. Li J. Gödecke T. Chen S.N. Imai A. Lankin D.C. Farnsworth N.R. Pauli G.F. van Breemen R.B. Nikolić D. in vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. Xenobiotica 2011 41 12 1021 1030 10.3109/00498254.2011.603385 21827327
    [Google Scholar]
  193. Siwek M. Woroń J. Wrzosek A. Gupało J. Chrobak A.A. Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs. Front. Pharmacol. 2023 14 1271776 10.3389/fphar.2023.1271776 37829299
    [Google Scholar]
  194. Feltrin C. Farias I.V. Sandjo L.P. Reginatto F.H. Simões C.M.O. Effects of standardized medicinal plant extracts on drug metabolism mediated by CYP3A4 and CYP2D6 enzymes. Chem. Res. Toxicol. 2020 33 9 2408 2419 10.1021/acs.chemrestox.0c00182 32786546
    [Google Scholar]
  195. Pang X. Cheng J. Krausz K.W. Guo D. Gonzalez F.J. Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica 2011 41 2 112 123 10.3109/00498254.2010.527021 20979450
    [Google Scholar]
  196. Ho S.H.Y. Singh M. Holloway A.C. Crankshaw D.J. The effects of commercial preparations of herbal supplements commonly used by women on the biotransformation of fluorogenic substrates by human cytochromes P450. Phytother. Res. 2011 25 7 983 989 10.1002/ptr.3371 21213356
    [Google Scholar]
  197. Mohamed M.E.F. Frye R.F. Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab. Dispos. 2011 39 9 1522 1528 10.1124/dmd.111.039602 21632963
    [Google Scholar]
  198. Yu W. Cai S. Zhao J. Hu S. Zang C. Xu J. Hu L. Beyond genome: Advanced omics progress of Panax ginseng. Plant Sci. 2024 341 112022 10.1016/j.plantsci.2024.112022 38311250
    [Google Scholar]
  199. Zhou Z. Li M. Zhang Z. Song Z. Xu J. Zhang M. Gong M. Overview of Panax ginseng and its active ingredients protective mechanism on cardiovascular diseases. J. Ethnopharmacol. 2024 334 118506 10.1016/j.jep.2024.118506 38964625
    [Google Scholar]
  200. Ru W. Wang D. Xu Y. He X. Sun Y.E. Qian L. Zhou X. Qin Y. Chemical constituents and bioactivities of Panax ginseng (C. A. Mey.). Drug Discov. Ther. 2015 9 1 23 32 10.5582/ddt.2015.01004 25788049
    [Google Scholar]
  201. Malati C.Y. Robertson S.M. Hunt J.D. Chairez C. Alfaro R.M. Kovacs J.A. Penzak S.R. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J. Clin. Pharmacol. 2012 52 6 932 939 10.1177/0091270011407194 21646440
    [Google Scholar]
  202. Ramanathan M.R. Penzak S.R. Pharmacokinetic drug interactions with Panax ginseng. Eur. J. Drug Metab. Pharmacokinet. 2017 42 4 545 557 10.1007/s13318‑016‑0387‑5 27864798
    [Google Scholar]
  203. Deng Y. Du J. He X. Dong Y.X. Wang X.L. Zeng Y.M. Wu X.L. Chen M. Du F.F. Wang F.Q. Rao Y. Wang L.L. Hua Y.F. Dong M.L. Yang J.L. Li C. Risk assessment of CYP3A induction by ginsenoside’s metabolites from oral Panax notoginseng (sanqi) extract. J. Ethnopharmacol. 2025 349 119864 10.1016/j.jep.2025.119864 40274033
    [Google Scholar]
  204. Seong S.J. Kang W.Y. Heo J.K. Jo J. Choi W.G. Liu K.H. Lee S. Choi M.K. Han Y.H. Lee H.S. Ohk B. Lee H.W. Song I.S. Yoon Y.R. A comprehensive in vivo and in vitro assessment of the drug interaction potential of red ginseng. Clin. Ther. 2018 40 8 1322 1337 10.1016/j.clinthera.2018.06.017 30078466
    [Google Scholar]
  205. Xie Y. Wang C. Herb–drug interactions between Panax notoginseng or its biologically active compounds and therapeutic drugs: A comprehensive pharmacodynamic and pharmacokinetic review. J. Ethnopharmacol. 2023 307 116156 10.1016/j.jep.2023.116156 36754189
    [Google Scholar]
  206. Yan J. Gu Q. Meng C. Liu J. Liu F. Xia C. Panaxytriol upregulates CYP3A4 expression through the interaction between nuclear regulators and DNA response elements. J. Ethnopharmacol. 2023 310 116398 10.1016/j.jep.2023.116398 36948264
    [Google Scholar]
  207. Kim M.G. Kim Y. Jeon J.Y. Kim D.S. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach. Br. J. Clin. Pharmacol. 2016 82 6 1580 1590 10.1111/bcp.13080 27495955
    [Google Scholar]
  208. Park J.D. Metabolism and drug interactions of Korean ginseng based on the pharmacokinetic properties of ginsenosides: Current status and future perspectives. J. Ginseng Res. 2024 48 3 253 265 10.1016/j.jgr.2024.02.003 38707645
    [Google Scholar]
  209. Calderón M.M. Chairez C.L. Gordon L.A. Alfaro R.M. Kovacs J.A. Penzak S.R. Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers. Pharmacotherapy 2014 34 11 1151 1158 10.1002/phar.1473 25142999
    [Google Scholar]
  210. Pastorino G. Cornara L. Soares S. Rodrigues F. Oliveira M.B.P.P. Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review. Phytother. Res. 2018 32 12 2323 2339 10.1002/ptr.6178 30117204
    [Google Scholar]
  211. El-Saber Batiha G. Magdy Beshbishy A. El-Mleeh A. Abdel-Daim M.M. Prasad Devkota H. Traditional uses, bioactive chemical constituents, and pharmacological and toxicological activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules 2020 10 3 352 10.3390/biom10030352 32106571
    [Google Scholar]
  212. He W. Wu J.J. Ning J. Hou J. Xin H. He Y.Q. Ge G.B. Xu W. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice. Toxicol. in vitro 2015 29 7 1569 1576 10.1016/j.tiv.2015.06.014 26100226
    [Google Scholar]
  213. Chen X. Wang T. Wang K. Peng T. Zhang Y. Ren X. Mechanistic insights into Licorice-Evodiae Fructus interaction: UPLC-MS/MS-based hepatotoxic metabolite detection and CYP3A4 regulation study. J. Pharm. Biomed. Anal. 2025 264 116985 10.1016/j.jpba.2025.116985 40424879
    [Google Scholar]
  214. Chen L. Nikolic D. Li G. Liu J. van Breemen R.B. in vitro inhibition of human cytochrome P450 enzymes by licoisoflavone B from Glycyrrhiza uralensis Fisch. ex DC. Toxicol. Sci. 2023 196 1 16 24 10.1093/toxsci/kfad079 37535691
    [Google Scholar]
  215. Wang X. Peng Y. Jing X. Qian D. Tang Y. Duan J. in vitro and in vivo assessment of CYP2C9-mediated herb–herb interaction of Euphorbiae Pekinensis Radix and Glycyrrhizae Radix. Front. Pharmacol. 2014 5 186 10.3389/fphar.2014.00186 25202272
    [Google Scholar]
  216. Doohan P.T. Oldfield L.D. Arnold J.C. Anderson L.L. Cannabinoid interactions with cytochrome P450 drug metabolism: A full-spectrum characterization. AAPS J. 2021 23 4 91 10.1208/s12248‑021‑00616‑7 34181150
    [Google Scholar]
  217. Bansal S. Zamarripa C.A. Spindle T.R. Weerts E.M. Thummel K.E. Vandrey R. Paine M.F. Unadkat J.D. Evaluation of cytochrome P450-Mediated Cannabinoid-Drug interactions in healthy adult participants. Clin. Pharmacol. Ther. 2023 114 3 693 703 10.1002/cpt.2973 37313955
    [Google Scholar]
  218. Bansal S. Paine M.F. Unadkat J.D. Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes. Drug Metab. Dispos. 2022 50 4 351 360 10.1124/dmd.121.000734 35115300
    [Google Scholar]
  219. Nasrin S. Watson C.J.W. Perez-Paramo Y.X. Lazarus P. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metab. Dispos. 2021 49 12 1070 1080 10.1124/dmd.121.000442 34493602
    [Google Scholar]
  220. Nascimento M.L. do Nascimento S.B. Lima E.S.P. de Oliveira F.M. dos Santos R.R. Cesar I.C. de Castro W.V. Evaluation of the effects of extracts containing valeriana officinalis and piper methysticum on the activities of cytochrome P450 3a and p-glycoprotein. Planta Med. 2024 90 10 792 800 10.1055/a‑2360‑4808 39013429
    [Google Scholar]
  221. Bouquié R. Deslandes G. Mazaré H. Cogné M. Mahé J. Grégoire M. Jolliet P. Cannabis and anticancer drugs: Societal usage and expected pharmacological interactions – a review. Fundam. Clin. Pharmacol. 2018 32 5 462 484 10.1111/fcp.12373 29660159
    [Google Scholar]
  222. Vigano M. Wang L. As’sadiq A. Samarani S. Ahmad A. Costiniuk C.T. Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy. Front. Immunol. 2025 16 1497829 10.3389/fimmu.2025.1497829 40109334
    [Google Scholar]
  223. Paduch M. Thomason A.R. Potential drug interactions between cannabinoids and its derivatives and oral anticoagulants. Hosp. Pharm. 2022 57 1 188 192 10.1177/0018578720985438 35521023
    [Google Scholar]
  224. Amaeze O. Eng H. Horlbogen L. Varma M.V.S. Slitt A. Cytochrome P450 enzyme inhibition and herb-drug interaction potential of medicinal plant extracts used for management of diabetes in nigeria. Eur. J. Drug Metab. Pharmacokinet. 2021 46 3 437 450 10.1007/s13318‑021‑00685‑1 33844145
    [Google Scholar]
  225. Wang P.F. Yang Y. Patel V. Neiner A. Kharasch E.D. Natural products inhibition of cytochrome P450 2b6 activity and methadone metabolism. Drug Metab. Dispos. 2024 52 3 252 265 10.1124/dmd.123.001578 38135504
    [Google Scholar]
  226. Husain I. Dale O.R. Martin K. Gurley B.J. Adams S.J. Avula B. Chittiboyina A.G. Khan I.A. Khan S.I. Screening of medicinal plants for possible herb-drug interactions through modulating nuclear receptors, drug-metabolizing enzymes and transporters. J. Ethnopharmacol. 2023 301 115822 10.1016/j.jep.2022.115822 36223846
    [Google Scholar]
  227. Sato Y. Sasaki T. Takahashi S. Kumagai T. Nagata K. Development of a highly reproducible system to evaluate inhibition of cytochrome P450 3A4 activity by natural medicines. J. Pharm. Pharm. Sci. 2015 18 4 316 327 10.18433/J3VK5G 26626238
    [Google Scholar]
  228. Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol. 2014 4 177 10.3389/fphar.2013.00177 24454289
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673428595251209114801
Loading
Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility
Bentham Science Publishers ; https://doi.org/10.2174/0109298673428595251209114801
/content/journals/cmc/10.2174/0109298673428595251209114801
/content/journals/cmc/10.2174/0109298673428595251209114801
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: phytoconstituents ; pharmacovigilance ; Herb-drug interaction ; cytochrome P450 ; medicinal plants ; CYP450 inhibitors ; CYP450 inducers

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test